A 68-year-old man with hypertension is started on an ACE inhibitor for blood pressure control. After 2 weeks, his serum creatinine rises from 1.0 to 1.4 mg/dL and potassium increases from 4.2 to 5.8 mEq/L. The patient is asymptomatic. What is the most appropriate next step in management?

Explanation

## Clinical Context: ACE Inhibitor–Induced Hyperkalemia and Renal Function Changes ### Pathophysiology of ACE Inhibitor Effects ACE inhibitors block angiotensin II formation, which has two key consequences: 1. **Renal hemodynamics**: Angiotensin II preferentially constricts the efferent arteriole of the glomerulus. When ACE inhibitors block this, efferent arteriole dilation occurs, reducing glomerular filtration pressure and transiently raising creatinine. 2. **Aldosterone suppression**: Reduced angiotensin II → decreased aldosterone → impaired renal potassium excretion → hyperkalemia. **Key Point:** A modest rise in serum creatinine (10–30%) and mild hyperkalemia in the first 1–2 weeks after ACE inhibitor initiation is *expected* and often *self-limited*. This does NOT mandate immediate discontinuation in an asymptomatic patient. ### Management Algorithm ```mermaid flowchart TD A["ACE inhibitor started"]:::action --> B{"Creatinine rise & hyperkalemia"}:::decision B -->|"Asymptomatic, mild rise"| C["Recheck in 1–2 weeks"]:::action C --> D{"Stable or improving?"}:::decision D -->|"Yes"| E["Continue ACE inhibitor"]:::action D -->|"No"| F["Discontinue & switch agent"]:::action B -->|"Symptomatic or severe"| F B -->|"Creatinine >30% rise or K >6.5"| F ``` ### Why Watchful Waiting (Option 3) Is Correct **High-Yield:** Stabilization typically occurs within 1–2 weeks. If creatinine and potassium plateau or decline, the ACE inhibitor can be safely continued. This preserves the cardio-renal protective benefits of ACE inhibition, especially in hypertension and chronic kidney disease. **Clinical Pearl:** The "acute rise" in creatinine reflects a beneficial reduction in hyperfiltration, not true nephron loss. Continuing the drug often leads to long-term renal protection. ### Why Each Distractor Is Wrong | Option | Why It's Wrong | |--------|---------------| | **Option 0** (Continue without monitoring) | Ignores the need to confirm stability; if hyperkalemia or creatinine worsens, delayed intervention increases risk of arrhythmia or acute kidney injury. | | **Option 1** (Immediate discontinuation) | Premature cessation in an asymptomatic patient discards a proven cardio-renal protective agent; most patients stabilize within 1–2 weeks. | | **Option 3** (Add potassium-sparing diuretic) | Compounds hyperkalemia risk; adding another potassium-retaining agent without addressing the root cause is contraindicated. |